Better benefits start here
Prime integrates with health plans for total drug management — no matter where medicine happens or how its reimbursed. We’re member-centric, provider-aligned and data-driven. And we’re here to help make better, more affordable care easier for everyone.
Blue + Prime
National scale, local control
Prime was created to partner with non-profit Blue health plans, trusted in communities across America. Our integrated model combines national scale with local control to help improve care and lower costs for your clients.
Thought leadership
Employer groups
Our connected approach helps life be easier for employers. Members get the medicine they need to feel better and live well. Employers can choose products and services that help lower pharmacy benefit costs and improve health outcomes — with less disruption for employees.
Health plans
Created by health plans to be an integrated partner, that unique relationship gives us deeper access to the medical data to help close gaps in care and create an airtight seal on the pharmacy/medical connection. No other pharmacy benefit manager can offer Prime’s level of integration.
Our solutions
We take a deeply integrated, channel independent, holistic approach to designing products that manage cost and provide smarter care that’s right for each person.
Our approach
We are connected where medicines play a role to unlock better, more affordable care.
Our story
Built on the strength from a unique Blue + Prime foundation, we’ve grown from a small pharmacy benefit manager (PBM) to a leading total drug management enterprise.
Related research
Drug pipeline updates
December 6, 2021
Prader-Willi Syndrome may get a new treatment option in late December
Prader-Willi syndrome (PWS) is a genetic, multi-system disorder that affects approximately 9,000 to…
Drug pipeline updates
November 30, 2021
Biosimilar strategy for bevacizumab using MedDrive™
Avastin® (bevacizumab) from Genentech was first approved in 2004. It has received FDA…
Drug pipeline updates
November 23, 2021
MedDrive™ derives biosimilar savings from oncology monoclonal antibodies
MedDrive has identified cost-saving biosimilar strategies for three oncology biosimilars: rituximab (Rituxan®—reference drug)…